The nation’s rate of preterm birth—the largest contributor to infant death in the United States -- increased again in 2016, after nearly a decade of decline, earning the nation a “C” grade on the latest March of Dimes Premature Birth Report Card.
The rate of preterm birth rose in states across the country for a second year in a row. More than 380,000 babies are born preterm in the U.S. each year, facing a greater likelihood of death before their first birthday, lifelong disabilities or chronic health conditions. An additional 8,000 babies were born prematurely in 2016 due to the increase in the preterm birth rate between 2015 and 2016, the March of Dimes says.
To view the multimedia release go to:
https://www.multivu.com/players/English/8189251-march-of-dimes-premature-birth-report-card-2017/
Many people suffer from eczema and various skin disorders that they don’t understand. The names for these skin disorders are numerous – eczema, psoriasis, dermatitis, hives, allergies, scales, and so on. Most standard medical treatments fail to cure or give lasting relief to some of these disorders. This makes it so frustrating for those with these diseases since even dermatologists and doctors find it difficult to find a cure for them.
Sickle cell disease (SCD) is an inherited, lifelong chronic disorder affecting nearly 100,000 Americans and a growing global health problem that will touch nearly 30 percent more people globally in the next three decades. Though new approaches to managing SCD have led to improvements in diagnosis and supportive care, people living with the disease still have severe complications to overcome. Many are unable to access quality care and are limited by a lack of effective treatment options.
In an effort to identify unmet medical needs for people with SCD, the American Society of Hematology (ASH), along with other groups, issued the State of Sickle Cell Disease: 2016 Report, evaluating the disease in four priority areas — access to care, training and professional education, research and clinical trials, and global health. The report shows that significant improvements are needed across all areas and that, though patients are living longer, the system of care needs to change to ensure a better quality of life. To address these challenges, ASH launched the Sickle Cell Disease Coalition along with more than 20 other organizations who are issuing a call to action that will amplify the voice of the SCD community, promote SCD awareness, and transform SCD care both in the United States and around the globe.
To view the multimedia release go to:
http://www.multivu.com/players/English/7903251-american-society-hematology-sickle-cell-coalition/
Third Box, a new resource for the unsure women in an unintended pregnancy, today announced results of a recent survey demonstrating that despite the current polarizing two-box political approaches, one in four women in unintended pregnancies are unsure of what to do. This data corresponds with the organization’s expansion of its reach to women in California regions, and its footprint across the country providing free medical and emotional care, in a space apart from ideology or politics, with no bias toward outcome.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7339251-third-box-sponsored-study-women-in-unintended-pregnancies-uncertain-national-expansion-campaign/
“We are all a heartbeat away from needing emergency care” is one of key messages of the Saving Millions campaign of the American College of Emergency Physicians (ACEP), highlighting the incredible value of emergency medicine to every community and the efficiency and economic benefits of medical care provided in the nation’s emergency departments. http://www.acep.org/savingmillions.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7253451-american-college-of-emergency-physicians-saving-millions-campaign/
St. Catherine Hospital from Croatia has been named as one of the finalists, and Ruban d’Honneur recipients, in the 2016/17 European Business Awards sponsored by RSM.
It is one of only 110 finalists announced after over 33,000 businesses were engaged in the competition, and was chosen by a panel of independent judges because it displayed the core values of innovation, ethics and success.
The company will now undertake an in depth face-to-face interview, and will find out if it is a winner of one of the 11 categories at a Gala Final on May 4 in Dubrovnik.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8037951-st-catherine-hospital-business-awards/
St. Jude Children’s Research Hospital is naming the institution’s principal research tower after Donald Pinkel, M.D., whose legacy of driving progress toward advancing cures for pediatric catastrophic diseases continues at the institution today.
When St. Jude was established 55 years ago, Pinkel, the hospital’s first medical director, committed to finding cures for childhood cancer, leading to groundbreaking treatments that saved countless children’s lives. Many of these cancers were deemed incurable prior to Pinkel’s research, but his distinct approach to eradicating diseases established a model for how cancers could be treated.
To view the multimedia release go to:
https://www.multivu.com/players/English/7924752-st-jude-childrens-research-hospital-donald-pinkel-tower/
Adolescents and young adults with a severe inherited immunodeficiency disorder improved following treatment with novel gene therapy developed at St. Jude Children’s Research Hospital and at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The results of this study appear today in the journal Science Translational Medicine.
The study involved five males with X-linked severe combined immunodeficiency disease (SCID-X1), also known as “Bubble Boy” disease, who were all treated at NIAID. This inherited disorder involves a mutation in the IL2RG gene that affects males and occurs in 1 of every 50,000 to 100,000 live births, leaving them with little to no immune protection.
To view the multimedia release go to:
http://www.multivu.com/players/English/7808651-st-jude-gene-therapy-results/
Today, Church & Dwight, Co., Inc., the makers of First Response™ pregnancy and ovulation tests, announced the launch of First Response™ Pregnancy PRO Digital Pregnancy Test & App Access – their latest innovation and the first and only Bluetooth Smart-enabled pregnancy test on the market. First Response™ Pregnancy PRO connects to a woman’s smart device through a mobile application. Once synced, the app provides her with pregnancy-related content only available with Pregnancy PRO, and delivers a personalized user experience throughout her entire pregnancy journey.
“We are thrilled to be unveiling the next generation of in-home pregnancy testing on a stage like CES, where so many technological advancements have made their debut,” said Stacey Feldman, Vice President of Marketing, Church & Dwight. “With Pregnancy PRO, we’ve leveraged unique consumer insights to develop a product that not only revolutionizes the pregnancy test category, but more importantly, provides women with the information they need during their journey.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7725251-first-response-pregnancy-pro/
Varian Medical Systems (NYSE: VAR) today is introducing the Halcyon™ system, an entirely new device for cancer treatment. Engineered to revolutionize clinical workflow, Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT). This new treatment system is designed to expand the availability of high quality cancer care globally and help save the lives of millions more cancer patients.
“The global cancer challenge is enormous,” said Kolleen Kennedy, president of Varian's Oncology Systems business. “It is expected that there will be 24.6 million cancer cases diagnosed annually by 2030, and there is an acute shortage of equipment and trained clinicians. With the innovations in this new technology platform, the system will deliver high quality Halcyon treatments that empower clinicians to care for many more patients. At Varian we are very excited with the introduction of Halcyon to be taking another big step toward advancing cost-effective cancer care worldwide.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8065951-varian-medical-systems-halcyon-cancer-treatment/
Today on Rare Disease Day, My Life, Our Future, a national program founded by leaders in the bleeding disorder community, including Bloodworks Northwest, the American Thrombosis and Hemostasis Network, the National Hemophilia Foundation and Bioverativ Inc., opened the largest research repository of its kind in the world to scientists. The My Life, Our Future Research Repository is a collection of genetic data and blood samples that are linked to phenotypic data from more than 5,000 people in the U.S. with hemophilia, a rare disorder that impairs the ability of one’s blood to clot. The My Life, Our Future Research Repository will allow researchers to advance the scientific understanding of the disorder, including genetic differences that affect bleeding severity and reaction to certain treatments.
To view the multimedia release go to:
https://www.multivu.com/players/English/8046151-national-hemophilia-foundation-my-life-our-future/
https://www.medibazar.eu/
Medibazar is a story of a couple of doctors coming together to bring together products that help you elevate yourself while being COMFORTABLE. CARING. COMPASSIONATE…
